What to Try for PTSD When Therapy and Medication Aren't Enough

Standard PTSD Treatments and What They Target

First-line, evidence-based treatments for PTSD recognized by the APA and VA/DoD practice guidelines include trauma-focused psychotherapies and FDA-approved medications.^1,2 Specific psychotherapies like prolonged exposure, cognitive processing therapy, and EMDR are considered the standard of care. FDA-approved medications for PTSD primarily include the SSRIs sertraline and paroxetine.

Trauma-focused therapies work by helping you process and reframe traumatic memories so they lose their emotional charge. SSRIs modulate serotonin signaling to reduce the intensity of specific PTSD symptom clusters.

• Intrusive memories: Recurrent, unwanted distressing memories, flashbacks, or nightmares of the traumatic event.
• Avoidance: Actively staying away from places, activities, or people that trigger memories of the trauma.
• Negative cognition and mood: Persistent distorted beliefs about oneself, feelings of detachment, or an inability to experience positive emotions.
• Hyperarousal: Physiological reactivity including hypervigilance, an exaggerated startle response, irritability, and sleep disturbances.

These treatments carry the APA's strongest recommendation and produce meaningful improvement in a majority of patients, but response is not universal. APA guidelines acknowledge that a substantial proportion of patients do not achieve full remission with first-line care alone, and residual symptoms are common even among responders.¹ When initial approaches fall short, knowing which factors to reassess can make the difference.

Reasons PTSD Symptoms Can Persist After Therapy and Medication

Treatment-resistant PTSD or partial response occurs when symptoms improve but do not resolve enough to restore daily functioning. Persistent symptoms do not mean your condition is untreatable; several practical and biological factors can influence how well you respond to a specific intervention.

• Trauma complexity: Multiple or prolonged traumatic exposures, often called complex PTSD, may not respond fully to protocols designed for single-incident trauma.
• Comorbid conditions: Co-occurring depression, substance use disorders, or chronic pain can blunt therapeutic response and require their own targeted interventions.
• Therapy tolerability: Trauma-focused therapies require sustained engagement with distressing material. Some people cannot tolerate the exposure component, leading to dropout or avoidance within treatment.
• Medication fit: SSRIs address serotonin pathways but do not target every neurobiological mechanism involved in PTSD. Side effects or inadequate dosing can also limit their benefit.
• Practical barriers: Access, cost, scheduling, stigma, and a lack of trained trauma therapists all reduce the likelihood of completing an adequate trial of evidence-based care.

When symptoms persist without adequate intervention, functional impairment tends to deepen over time. The risk of comorbid depression, substance use disorders, and suicidality also increases significantly.¹¹ Persistent symptoms often mean the specific approach, dose, duration, or combination was not the right fit. A medical reassessment can identify a clearer path forward.

Steps to Take Before You Switch or Add a New PTSD Treatment

Before pursuing advanced or additional interventions, a reassessment with your care team can reveal whether the current plan was fully optimized. The following process is a practical checklist to ensure you have a complete picture of your care. It is not a suggestion to delay new interventions.

1. Confirm the diagnosis: PTSD symptoms overlap with other conditions like major depressive disorder, generalized anxiety disorder, and traumatic brain injury. A thorough re-evaluation can ensure the treatment plan matches the actual medical picture.
2. Review medication dose and duration: SSRIs require adequate dosing for a sufficient duration before response can be fairly assessed. Ask your prescriber whether your 8 to 12 weeks at a therapeutic dose was truly adequate.
3. Evaluate therapy type and fit: Not all therapy is trauma-focused. If you received general supportive counseling rather than an evidence-based protocol like cognitive processing therapy or prolonged exposure, you may not have had an adequate trial. The therapeutic relationship also matters, as a poor fit can limit progress.
4. Assess combination therapy: Were medication and psychotherapy used together? If only one modality was tried, combining them may improve outcomes. If both were tried but results were limited, the combination itself may need reassessment to ensure coordination.
5. Address co-occurring conditions: Untreated depression, substance use, insomnia, or chronic pain can undermine PTSD recovery progress. Addressing these in parallel often improves overall response.
6. Identify practical barriers: Inconsistent attendance, lack of between-session practice, financial strain, or caregiver burden can all reduce therapeutic effectiveness. These factors do not necessarily reflect a true non-response to the modality itself.

Reassessing your care history ensures your next medical decision is informed and intentional.

Advanced PTSD Treatments to Discuss With a Provider

When first-line approaches have been optimized and symptoms persist, several additional options have evidence supporting their use for PTSD. These are not experimental curiosities. Each has a defined mechanism, a body of peer-reviewed research, and specific contexts where it may be appropriate.

The options below differ in mechanism, setting, evidence base, and accessibility. None is universally right for everyone, and each requires a provider evaluation to determine appropriateness. The goal is to give you enough information to have an informed conversation with your care team.

Ketamine-Assisted Therapy

Ketamine has been FDA-approved as an anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985.³ Decades of medical use establish it as a well-characterized medication with a long history, distinct from the first-line PTSD treatments discussed here.

Ketamine is an NMDA receptor modulator that can rapidly reduce PTSD symptoms by promoting neuroplasticity. Neuroplasticity is the brain's ability to form new neural connections and reorganize existing ones. Unlike SSRIs, which modulate serotonin over weeks, ketamine acts on the glutamate system and can produce noticeable changes within hours or days of the first session. More durable benefits typically develop over a supervised series of sessions.

Ketamine temporarily modulates glutamate signaling, which opens a window of enhanced neuroplasticity. Within that window, entrenched trauma-related thought patterns and fear responses become more amenable to change. The process is particularly effective when paired with therapeutic integration. Sessions are clinically-supervised, use sub-anesthetic therapeutic dosing,⁷ and are typically part of a defined treatment framework that includes preparation and integration support.

In a real-world analysis of 374 patients receiving at-home ketamine therapy for PTSD, 92.2% reported symptom improvement.⁶ Furthermore, 79.7% met criteria for response, and 60.7% reached full remission.⁶ Speed of response is notable, with 62% meeting response criteria after just two sessions.⁶

While no head-to-head trials have been performed and direct comparisons are limited by differences in study design, patient populations, and instruments, these outcomes compare favorably to published trials of standard first-line PTSD treatments. With the at-home ketamine therapy protocol producing 45% PCL-5 symptom reduction within a six-session program completed in four to six weeks.⁶ Comparatively, a randomized trial of prolonged exposure therapy in combat veterans showed 17% CAPS reduction at week 6, reaching 36% at the study's 24-week endpoint.⁴ Sertraline plus enhanced medication management in the same trial showed 27% at week 6, reaching 45% at week 24.⁴

Administered within a protocol-driven framework under medical oversight, ketamine-assisted therapy is an evidence-based PTSD option. It acts through a distinct neurobiological pathway from conventional treatments. It is not appropriate for everyone, and eligibility is determined through a comprehensive medical screening process.

Esketamine Nasal Spray

Esketamine, known by the brand name Spravato, is the S-enantiomer of ketamine delivered as a nasal spray. It acts on the same NMDA receptor pathway as ketamine and has shown rapid antidepressant effects in patients with treatment-resistant depression. A pilot study in patients with treatment-resistant depression and comorbid PTSD reported improvements in both depression and PTSD symptoms when esketamine was paired with an oral antidepressant and trauma-focused psychotherapy.¹⁴

Esketamine is administered in a Spravato REMS-certified facility. Patients self-administer the nasal spray under direct medical supervision, then remain on-site for at least two hours of monitoring after each dose.

Esketamine is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation, but it does not currently carry an FDA indication for PTSD. Because PTSD use is off-label, insurance typically does not cover the medication for that purpose, and availability for PTSD treatment is more limited than for treatment-resistant depression. Out-of-pocket per-session cost, combining the medication, facility fees, and required monitoring time, can be higher than at-home ketamine therapy. For patients considering esketamine specifically for PTSD, it is worth confirming the indication, insurance coverage, and total session cost with the prescribing provider before starting.

Stellate Ganglion Block

A stellate ganglion block is an injection of local anesthetic into the stellate ganglion, a cluster of sympathetic nerves in the neck. It was originally developed for pain management. It has been studied as an intervention for PTSD-related hyperarousal symptoms, particularly the exaggerated fight-or-flight response.

The injection temporarily interrupts sympathetic nervous system signaling. The interruption may reduce the physiological hyperarousal, such as elevated heart rate and hypervigilance, that characterizes PTSD. The procedure is performed by an anesthesiologist or pain specialist, typically in an outpatient setting, and takes approximately 15 to 30 minutes. Published randomized controlled trials and case series have reported symptom reduction in PTSD hyperarousal symptoms.¹² The evidence base is smaller and less mature than that for ketamine or trauma-focused psychotherapy.

The block targets physiological hyperarousal specifically rather than the full spectrum of PTSD symptoms. It may be most relevant for individuals whose dominant symptoms are autonomic, such as exaggerated startle or sleep disruption driven by physiological arousal. A specialist can help determine whether the block is appropriate as a standalone intervention or an adjunct to other treatments.

Transcranial Magnetic Stimulation

Transcranial magnetic stimulation is a noninvasive neuromodulation technique that uses magnetic pulses to stimulate specific regions of the brain. The FDA has cleared TMS for treatment-resistant depression and OCD. It has been studied for PTSD, though it does not currently carry an FDA clearance specifically for the condition.

A coil placed against the scalp delivers focused magnetic pulses that modulate neural activity in targeted brain regions, such as the dorsolateral prefrontal cortex. A typical course involves daily sessions over several weeks, each lasting approximately 20 to 40 minutes, in an outpatient setting. No anesthesia or sedation is required. Multiple randomized controlled trials have shown symptom reduction, particularly when targeting brain regions involved in fear processing and emotional regulation.¹³ Results vary, and the optimal protocol for PTSD is still being refined.

The approach is noninvasive and does not involve medication. The approach may appeal to individuals who prefer non-pharmacological options or who have contraindications to certain medications. The requirement for daily in-person sessions over several weeks is a practical consideration. Whether TMS is appropriate depends on your symptom profile and care history, which your provider can evaluate with you.

When to Seek a Higher Level of PTSD Care

Some situations call for more intensive or immediate care than outpatient sessions can provide. Recognizing the signals is part of informed self-advocacy.

Seek immediate help if you experience:

• Active suicidal ideation or a plan to harm yourself (call 988 Suicide & Crisis Lifeline or go to the nearest emergency department).
• Severe dissociative episodes that impair your ability to stay safe.
• Psychotic symptoms, such as hallucinations or delusions, that are new or worsening.

Discuss a higher level of care with your provider if:

• Symptoms are worsening despite optimized outpatient care.
• Co-occurring substance use is escalating and not being addressed in your current plan.
• Daily functioning regarding work, relationships, or self-care has deteriorated significantly.
• You feel unable to engage in or tolerate outpatient therapy sessions.

Higher levels of care include intensive outpatient programs, partial hospitalization programs, and residential treatment. Each offers more support than standard outpatient sessions. Seeking a higher level of care is not a failure. The choice is a medical decision that matches the intensity of care to the severity and complexity of symptoms. Your care team can help you evaluate which level is appropriate.

Healing From PTSD Is Possible Even When the First Approach Doesn't Work

First-line PTSD treatments work for many people, but when they do not fully resolve symptoms, it does not mean healing is out of reach. Reassessment, optimization, and evidence-based advanced approaches offer real paths forward. Whether the path means refining your current plan, exploring ketamine-assisted therapy, or discussing another modality with your provider, the goal is the same. You are looking for the approach that fits your neurobiology, your history, and your life.

PTSD healing is not always linear. Healing may look like meaningful symptom reduction and restored functioning rather than the complete absence of all trauma-related responses. The reduction is a medically meaningful and life-changing outcome.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine carries abuse and dependence risk, but in supervised, protocol-driven treatment that risk is reduced by clinician screening, structured dosing, and monitoring within a defined course of care. Ketamine is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment.⁸ Schedule III Controlled Substance - DEA regulations apply.